Cargando…
Personalized medicine: paradigm shift in ALK positive non-small cell lung cancer: a case report
BACKGROUND: Since the identification of multiple therapeutic targets, as is the case of anaplastic lymphoma kinase (ALK) translocation, the paradigm of treating patients with non-small cell lung cancer (NSCLC) has improved. In order to guarantee the possibility of longer survival outcomes with a bet...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474633/ https://www.ncbi.nlm.nih.gov/pubmed/37658466 http://dx.doi.org/10.1186/s13256-023-04107-5 |